In response to the R&D productivity crisis affecting the pharmaceutical industry, “big pharma” is seeking to source therapeutics from small and medium sized enterprises (SMEs). In this seminar, Dr Michael Hopkins of the University of Sussex will discuss his research tracking the SMEs that have played a part in projects reaching late stage clinical trials.

In response to the R&D productivity crisis affecting the pharmaceutical industry, "big pharma" is seeking to source therapeutics from small and medium sized enterprises (SMEs). In this seminar, Dr Michael Hopkins of the University of Sussex will discuss his research tracking the SMEs that have played a part in projects reaching late stage clinical trials. The analysis is based on a novel, comprehensive data set that covers all 247 active R&D UK therapeutics firms, both public and private, founded between 1980 and 2009.

Dr Hopkins's research follows these SMEs for their entire funding cycles, revealing important information about the sector as a whole.  The results show which financing strategies are most likely to generate successful projects and identify areas of concern to policy makers.

This Lunchtime Seminar will be held on 4 July, 2012, beginning at noon and ending promptly at 2.00 PM, at the Marriott London County Hall, County Hall, Westminster Bridge Road, London SE1 7PB.  For additional information, please click here.

Seating is limited.  Please click here to register.

Related OHE publication available for download: Riccaboni, M. (2012) Is there a productivity crisis in pharmaceutical R&D? Seminar Briefing. 11. London: Office of Health Economics.